Advertisement
Original article| Volume 113, ISSUE 5, P598-603, May 1989

Evaluation of prostate-specific antigen as a marker for adenocarcinoma of the prostate

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Serum prostate-specific antigen (PSA) concentrations were measured in samples from 437 subjects, including patients with prostate cancer, patients with benign prostate hyperplasia (BPH), and patients with genitourinary cancer or benign genitourinary diseases other than prostatic, as well as patients who had undergone prostatectomy and healthy controls. PSA concentration was elevated (>10 ng/ml) in 84.4% of the patients with prostate cancer, in 14.1% of the patients with BPH, and in 10% of the patients with genitourinary cancer (as compared with 2% of the patients with benign genitourinary diseases). PSA concentration was not elevated in any of the patients who had undergone prostatectomy nor in the controls. In the same samples, the level of prostatic acid phosphatase (PAP) was increased (>4 Math Eq) in only 55.6% of the patients with prostate cancer and in 7.4% of the patients with BPH. According to these findings, the sensitivity of the test is 84.4% (55.6% for PAP) and the specificity is 92.9% (94.9% for PAP). The increase in PSA concentration in BPH correlates well with the prostate mass (γ = 0.794), although there was no patient with a prostate weight higher than 30 gm and a PSA concentration lower than 5 ng/ml, and all patients with PSA concentrations lower than 4 ng/ml had prostate weights of less than 10 gm.

      Abbreviations:

      BPH (benign prostate hyperplasia), PAP (prostatic acid phosphatase), PSA (prostate-specific antigen)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Scott RCr
        • Hutchnik DL
        • Laskowski TZ
        • Schmalhorst WH
        Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance.
        J Urol. 1969; 101: 602-609
        • Silverberg E
        Cancer statistics 1982.
        CA. 1982; 32: 15-42
        • Israel Cancer Registry
        Cancer in Israel, facts and figures 1972–1976.
        Ministry of Health, Jerusalem1982
        • Servadio C
        • Mukamel E
        • Kahan E
        Carcinoma of prostate in Israel: some epidemiological and therapeutic considerations.
        Prostate. 1984; 5: 375-378
        • Guinan P
        • Bush I
        • Ray V
        • Vieth R
        • Rao R
        • Bhatti R
        The accuracy of the rectal examination in the diagnosis of prostate carcinoma.
        N Engl J Med. 1980; 303: 499-503
        • Schacht MJ
        • Garnett JE
        • Grayhack JT
        Biochemical markers in prostatic cancer.
        Urol Clin North Am. 1984; 11: 253-267
        • Wang MC
        • Valenzuela LA
        • Murphy GP
        • Chu TM
        Purification of a human prostate specific antigen.
        Invest Urol. 1979; 17: 159-163
        • Lilja H
        A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein.
        J Clin Invest. 1985; 76: 1899-1903
        • Nadji M
        • Tabei SZ
        • Castro A
        • et al.
        Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasma.
        Cancer. 1981; 48: 1229-1232
        • Wang MC
        • Papsidero LD
        • Kuriyama M
        • Valenzuela LA
        • Murphy GP
        • Chu TM
        Prostatic antigen: a new potential marker for prostatic cancer.
        Prostate. 1981; 2: 89-96
        • Frankel AE
        • Rouse RV
        • Wang MC
        • Chu TM
        • Herzenberg LA
        Monoclonal antibodies to a human prostate antigen.
        Cancer Res. 1982; 42: 3714-3718
        • Papsidero LD
        • Wang MC
        • Valenzuela LA
        • Murphy GP
        • Chu TM
        A prostate antigen in sera of prostatic cancer patients.
        Cancer Res. 1980; 40: 2428-2432
        • Kuriyama M
        • Wang MC
        • Papsidero LD
        • et al.
        Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.
        Cancer Res. 1980; 40: 4658-4662
        • Siddall JK
        • Cooper EH
        • Newling DWW
        • Robinson MRG
        • Whelan P
        An evaluation of the immunochemical measurement of PAP and PSA in carcinoma of the prostate.
        Eur Urol. 1986; 12: 123-130
        • Ahmann FR
        • Schifman RB
        Prospective comparison between serum monoclonal PSA and acid phosphatase measurements in metastatic prostate cancer.
        J Urol. 1987; 137: 431-434
        • Killian LS
        • Yang N
        • Emrich LJ
        • et al.
        Prognostic importance of PSA for monitoring patients with stages B2 to D l prostate cancer.
        Cancer Res. 1985; 45: 886-891
        • Myrtle JF
        • Klimley PG
        • Ivor LP
        • Bruni JF
        Clinical utility of PSA in the management of prostate cancer.
        Advances in Cancer Diagnosis. 1986; 6: 1
        • Kuriyama M
        • Wang MC
        • Lee CL
        • et al.
        Multiple marker evaluation in prostate cancer with the use of tissue-specific antigen.
        JNCI. 1982; 69: 99-105
        • Pontes JE
        • Chu TM
        • Slack N
        • Karr J
        • Murphy GP
        Serum prostatic artigen measurement in localized prostatic cancer: correlation with clinical course.
        J Urol. 1982; 128: 1216-1218
        • McNeal JE
        • Bostwick DG
        • Kindrrachuk RA
        • Redwine EA
        • Freiha FS
        • Stamey TA
        Patterns of progression in prostate cancer.
        Lancet. 1986; 1: 60-63
        • Takenchi T
        • Kuriyama M
        • Fujihiro S
        • Fugimoti Y
        • Okano M
        • Nishiura T
        Evaluation of serum PSA in urologic cancers.
        J Surg Oncol. 1983; 24: 157-160
        • Kovi J
        Microscopic differential diagnosis of small acinar adenocarcinoma of prostate.
        Pathol Annu. 1985; 20: 157-196
        • Stamey TA
        • Yang N
        • Hay AR
        • McNeal JE
        • Freiha FS
        • Redwine E
        Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.
        N Engl J Med. 1987; 317: 909-916
        • Yam LT
        • Janckila AJ
        • LiCY
        • Lam WKW
        Presence of “prostatic” acid phosphatase in human neutrophils.
        Invest Urol. 1981; 19: 34-38
        • Gibb I
        • Wilson LA
        • Powell PH
        • Tarbit I
        • Pratt D
        • Hall RR
        Immunological and colorimetric determination of PAP—technical and clinical reappraisal in symptomatic patients.
        Clin Chem. 1986; 32: 1760-1776
        • Brechman WD
        • Lastinger LB
        • Sedor F
        Unpredictable fluctuations in serum AP activity in prostatic cancer.
        JAMA. 1981; 245: 2501-2504
        • Schifman RB
        • Ahmann FR
        • Elvick A
        • Ahmann M
        • Coulis K
        • Brawer MK
        Analytical and physiological characteristics of PSA and PAP in serum compared.
        Clin Chem. 1987; 33: 2086-2091
        • Guinan P
        • Bhatti R
        • Ray P
        An evaluation of prostate specific antigen in prostatic cancer.
        J Urol. 1987; 137: 686-689
        • Loor R
        • M'Timkulu T
        • Jung N
        • et al.
        Measurement of prostate tissue-specific markers: PSA and PAP.
        J Clin Immunoassay. 1986; 9: 153-158